^
BIOMARKER:

PD-L1 overexpression

i
Other names: PD-L1, CD274, HPD-L1, PD-L1, B7H1, PDL1, Programmed death ligand 1, B7-H1, B7-H, PDCD1L1, PDCD1LG1, PDCD1 Ligand 1, B7 homolog 1, CD274 Antigen, Programmed cell death 1 ligand 1, CD274 molecule
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
Related biomarkers:
PD-L1 overexpression
Non Small Cell Lung Cancer
sintilimab
Sensitive
:
C3
BMC Cancer - 3 weeks - (New C3)
PD-L1 overexpression
Non Small Cell Lung Cancer
cemiplimab
Sensitive
:
A1
PD-L1 overexpression
Non Small Cell Lung Cancer
atezolizumab
Sensitive
:
A1
PD-L1 overexpression
Urothelial Cancer
tislelizumab
Sensitive
:
A1
PD-L1 overexpression
Non Small Cell Lung Cancer
pembrolizumab
Sensitive
:
A2
PD-L1 overexpression
Lung Non-Squamous Non-Small Cell Cancer
pembrolizumab
Sensitive
:
A2
PD-L1 overexpression
Non Small Cell Lung Cancer
bevacizumab + atezolizumab
Sensitive
:
A2
PD-L1 overexpression
Non Small Cell Lung Cancer
bevacizumab
Sensitive
:
A2
PD-L1 overexpression
Lung Non-Small Cell Squamous Cancer
atezolizumab
Sensitive
:
A2
PD-L1 overexpression
Lung Non-Small Cell Squamous Cancer
pembrolizumab
Sensitive
:
A2
PD-L1 overexpression
Lung Non-Small Cell Squamous Cancer
nivolumab + ipilimumab
Sensitive
:
A2
PD-L1 overexpression
Lung Non-Small Cell Squamous Cancer
cemiplimab
Sensitive
:
A2
PD-L1 overexpression
Non Small Cell Lung Cancer
atezolizumab + RG6058
Sensitive
:
B
PD-L1 overexpression
Non Small Cell Lung Cancer
carboplatin + albumin-bound paclitaxel
Sensitive
:
B
PD-L1 overexpression
Non Small Cell Lung Cancer
carboplatin + gemcitabine
Sensitive
:
B
PD-L1 overexpression
Non Small Cell Lung Cancer
cisplatin + albumin-bound paclitaxel
Sensitive
:
B
PD-L1 overexpression
Non Small Cell Lung Cancer
GC
Sensitive
:
B
PD-L1 overexpression
Non Small Cell Lung Cancer
carboplatin + pemetrexed
Sensitive
:
B
PD-L1 overexpression
Non Small Cell Lung Cancer
cisplatin + pemetrexed
Sensitive
:
B
PD-L1 overexpression
Gastroesophageal Cancer
PD1 inhibitor
Sensitive
:
B
PD-L1 overexpression
Gastroesophageal Cancer
PD-L1 inhibitor
Sensitive
:
B
PD-L1 overexpression
Triple Negative Breast Cancer
pembrolizumab
Sensitive
:
B
PD-L1 overexpression
Non Small Cell Lung Cancer
tislelizumab
Sensitive
:
B
PD-L1 overexpression
Urothelial Cancer
durvalumab
Sensitive
:
B
PD-L1 overexpression
Non Small Cell Lung Cancer
nivolumab
Sensitive
:
B
PD-L1 overexpression
Non Small Cell Lung Cancer
avelumab
Sensitive
:
B
PD-L1 overexpression
Squamous Cell Carcinoma of Head and Neck
durvalumab
Sensitive
:
B
PD-L1 overexpression
Esophageal Squamous Cell Carcinoma
pembrolizumab
Sensitive
:
B
PD-L1 overexpression
Gastric Cancer
pembrolizumab
Sensitive
:
B
PD-L1 overexpression
Gastroesophageal Junction Adenocarcinoma
pembrolizumab
Sensitive
:
B
PD-L1 overexpression
Prostate Cancer
atezolizumab + enzalutamide capsule
Sensitive
:
B
PD-L1 overexpression
Esophageal Adenocarcinoma
nivolumab
Sensitive
:
B
PD-L1 overexpression
Gastroesophageal Junction Adenocarcinoma
nivolumab
Sensitive
:
B